lapatinib has been researched along with Genetic Predisposition in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, S; Andersson, M; Armour, A; Aziz, Z; Briley, LP; Byrne, J; Crescenzo, R; Demetriou, G; Fraser, DJ; Gralow, J; Harris, L; Jackson, N; Jiang, Z; Mehta, A; Parham, LR; Perez, E; Piccart, M; Spraggs, CF; Toi, M; Warren, L; Williams, LS; Zujewski, JA | 1 |
| Cardon, LR; Cox, CJ; Curran, J; Ejlertsen, B; Finkelstein, DM; Goss, PE; McDonnell, SK; Parham, LR; Rappold, E; Schaid, DJ; Spraggs, CF | 1 |
| Briley, LP; Byrne, J; Goss, PE; King, KS; Parham, LR; Rappold, E; Spraggs, CF | 1 |
| Cheng, M; Conteh, AM; Craven, KE; Gore, J; Imasuen-Williams, IE; Korc, M | 1 |
| Amici, A; Andreani, C; Bartolacci, C; Belletti, B; Elexpuru Zabaleta, M; Galeazzi, R; Gambini, V; Garulli, C; Hysi, A; Iezzi, M; Kalogris, C; Marchini, C; Orlando, F; Pietrella, L; Provinciali, M; Tilio, M; Wang, J | 1 |
| Benusiglio, PR | 1 |
| Bing, N; Briley, LP; Budde, LR; Cardon, LR; Cox, CJ; King, KS; Mooser, VE; Preston, AJ; Spraggs, CF; Stein, SH; Whittaker, JC | 1 |
| de Azambuja, E; Metzger-Filho, O | 1 |
| Andersen, JB; Avital, I; Barbour, A; Blechacz, BR; Conner, EA; Factor, VM; Gillen, MC; Komuta, M; Roberts, LR; Roskams, T; Spee, B; Thorgeirsson, SS | 1 |
| Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A | 1 |
1 review(s) available for lapatinib and Genetic Predisposition
| Article | Year |
|---|---|
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Belgium; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Cholangiocarcinoma; Cluster Analysis; ErbB Receptors; Female; Gene Expression Profiling; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Laser Capture Microdissection; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Oligonucleotide Array Sequence Analysis; Patient Selection; Phenotype; Precision Medicine; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Queensland; Quinazolines; ras Proteins; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Trastuzumab; Tumor Microenvironment; United States | 2012 |
2 trial(s) available for lapatinib and Genetic Predisposition
| Article | Year |
|---|---|
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Genetic Predisposition to Disease; Genotype; HLA-DRB1 Chains; Humans; Lapatinib; Liver; Neoplasm Staging; Risk Factors; Taxoids; Trastuzumab | 2018 |
Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Genetic Predisposition to Disease; Genotype; HLA-DRB1 Chains; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
7 other study(ies) available for lapatinib and Genetic Predisposition
| Article | Year |
|---|---|
Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.
Topics: Alleles; Antineoplastic Agents; DNA; Drug Eruptions; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; HLA Antigens; Humans; Lapatinib; Polymorphism, Genetic; Quinazolines | 2015 |
Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Female; Gene Expression Profiling; Genes, Retinoblastoma; Genetic Predisposition to Disease; Humans; Lapatinib; Lymphangiogenesis; Male; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2016 |
Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Topics: Alternative Splicing; Animals; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Genetic Predisposition to Disease; Humans; Inhibitory Concentration 50; Lapatinib; Mammary Neoplasms, Experimental; Mice, Transgenic; Phenotype; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Receptor, ErbB-2; Signal Transduction; Time Factors | 2016 |
Focus on ERBB2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Genetic Predisposition to Disease; Humans; Lapatinib; Polymorphism, Genetic; Protein Binding; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; HLA-DQ alpha-Chains; HLA-DQ Antigens; Humans; Lapatinib; Liver; Liver Diseases; Liver Function Tests; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |